-
Mashup Score: 2Illumina and Pillar Biosciences partner to improve access to personalized cancer treatment options - 9 month(s) ago
Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, and Pillar Biosciences Inc., the pioneers of Decision Medicine™, today announced a strategic partnership to make Pillar’s suite of oncology assays commercially available globally as part of the Illumina portfolio of oncology products. The agreement will result in an unprecedented offering of complementary next-generation sequencing solutions that will enhance the efficiency, accuracy, and cost-effectiveness of oncology testing through advanced sequencing techniques, improving patient access to personalized cancer treatment options. “We are proud to partner with Pillar to provide products that will improve care for patients with advanced and high-risk cancer,” said Phil Febbo, chief medical officer of Illumina. “By leveraging Pillar’s targeted sequencing technology alongside Illumina’s state-of-the-art sequencing and bioinformatics solutions, we will enable rapid and focused genomic profiling
Source: investor.illumina.comCategories: Latest Headlines, Oncologists1Tweet
-
Mashup Score: 2
Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it has invested in six genomics startups for the fifth global funding cycle of Illumina Accelerator in the San Francisco Bay Area and Cambridge, UK. Illumina Accelerator is a world-class company creation engine focused on partnering with entrepreneurs to build breakthrough genomics…
Source: investor.illumina.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 10Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test - 3 year(s) ago
GRAIL will remain a separate and independent unit, pending ongoing regulatory and legal review Illumina, Inc. (NASDAQ: ILMN) announced today that it has acquired GRAIL, a healthcare company focused on life-saving early detection of multiple cancers, but will hold GRAIL as a separate company during the European Commission’s ongoing regulatory review. Illumina, the global leader in DNA sequencing,…
Source: investor.illumina.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 5
Updates Fiscal Year 2021 Revenue Guidance Illumina, Inc. (NASDAQ: ILMN) today announced preliminary revenue for the first quarter of fiscal year 2021 and updated its fiscal year 2021 revenue guidance. Subject to quarter-end closing adjustments, Illumina expects to report first quarter 2021 revenue of approximately $1,085 million, compared to $859 million in the first quarter of 2020. This…
Source: investor.illumina.comCategories: Healthcare Professionals, Latest HeadlinesTweet
Our partnership with @Pillar_Bio will combine their targeted panels with @illumina 's NGS and bioinformatics for rapid #genomic profiling of tumors when focused testing is needed. Improving care for patients with advanced and high-risk cancer, together. https://t.co/oR31IAvH3l